Business Announcement

To promote the advancement of engineering science and technology, lead engineering innovation, and guide global communities to focus on engineering endeavors, the journal Engineering of the Chinese Academy of Engineering is organizing the selection of the 2025 Top Ten Global Engineering Achievements. Nominations are now open to domestic and international scientific organizations and professionals for globally influential engineering accomplishments.

The American Heart Association and the Women’s National Football Conference celebrate season opening with player ambassador unveil

ATRI Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount of amyloid precursor protein (APP) for the potential treatment of Alzheimer’s disease (AD), which is initially being studied in adults with Down syndrome (DS) who have a genetic risk of developing AD. Those with Down syndrome are born with an extra chromosome that carries a gene pivotal to causing Alzheimer’s. The gene produces a protein that causes a buildup of plaques in the brain. By the time most people with Down syndrome hit age 40, they have already developed these plaques. It may take another decade or more to develop symptoms, but eventually up to nine in 10 people with Down syndrome are expected to develop Alzheimer’s disease. Seeking to change these odds, last month, researchers gave the first dose of an investigative drug to a participant in the new clinical trial, called the HERO study. The drug is designed to stop Alzheimer’s-causing plaques from forming in the brain. Led by Ionis Pharmaceuticals, with investigative oversight by ATRI Medical Director Michael Rafii, MD, PhD, the study is expected to run for two years with an initial 30 participants at sites across the U.S. and Europe.

The "PV Doctor", launched on 2 April 2025, is a spin-off from the Solar Energy Research Institute of Singapore (SERIS) at the National University of Singapore (NUS). It commercialises 15 years of in-depth research on PV system performance in different climates and on maximising energy yield – be it for well-operating (“healthy”) or under-performing (“sick”) installations.

Xiamen University (XMU) has joined the Bentham Science Institutional Membership Program.

The American College of Cardiology’s (ACC’s) five-year Strategic Plan includes a major initiative focused on transforming care delivery in new areas and recognizing the importance of delivering care within the communities where patients reside.¹ As part of this initiative, the ACC and MedAxiom, an ACC Company focused on cardiovascular organizational improvement solutions, are partnering on a series of care transformation resources designed to provide a framework for health systems to effectively integrate novel paradigms of care into their delivery models. 

Wiley announces the release of the second edition of Maurer, Meyer, Helfer, Weber: LC-HR-MS/MS Library of Drugs, Poisons, and Their Metabolites.